Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $117.60

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received a consensus rating of “Buy” from the twenty-two research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nineteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $117.60.

Several analysts have recently issued reports on KYMR shares. Stifel Nicolaus set a $114.00 target price on shares of Kymera Therapeutics in a research note on Monday, December 8th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Finally, Truist Financial increased their price target on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced its degrader candidate KT‑579 has entered first‑in‑human (Phase 1) testing — an important de‑risking milestone that validates the Pegasus platform and expands the company’s clinical-stage pipeline. Article Title
• Positive Sentiment: Management reported a large cash infusion (~$1.6B) that materially extends the company’s cash runway into 2029 and supports planned development (including KT‑621), reducing near‑term dilution risk. This funding, combined with ongoing program progress, is a key positive for valuation and execution. Article Title
• Positive Sentiment: Analyst sentiment remains constructive: Piper Sandler raised its price target to $140 and the consensus analyst posture is still broadly a “Buy,” supporting potential upside from upgrades and model revisions. Article Title
• Neutral Sentiment: Kymera reiterated plans to read out KT‑621 Phase IIb data in 2027 — a clear catalyst for 2027 but distant; this keeps the company in a development‑stage timeline where interim updates will matter to sentiment. Article Title
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.97) vs. consensus ($0.77) and revenue of $2.87M vs. $14.8M (down ~60% y/y). The larger loss and revenue shortfall triggered near‑term selling and raises questions on near‑term commercial/collaboration cadence. Article Title
• Negative Sentiment: Insider selling: CEO Nello Mainolfi sold 30,000 shares (~$2.7M). While not uncommon for executives to monetize, multiple recent sales may weigh on investor sentiment in the short term. Article Title

Kymera Therapeutics Stock Down 3.9%

Shares of Kymera Therapeutics stock opened at $91.35 on Friday. The company has a market cap of $7.46 billion, a PE ratio of -24.82 and a beta of 2.20. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $103.00. The business has a 50 day moving average price of $78.52 and a 200-day moving average price of $65.62.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm’s quarterly revenue was down 60.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.88) EPS. As a group, research analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In other Kymera Therapeutics news, insider Jared Gollob sold 49,307 shares of Kymera Therapeutics stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $88.67, for a total value of $4,372,051.69. Following the sale, the insider owned 109,992 shares of the company’s stock, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the completion of the transaction, the chief executive officer owned 666,195 shares in the company, valued at approximately $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 450,895 shares of company stock worth $40,486,151. 16.01% of the stock is owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently modified their holdings of KYMR. Virtu Financial LLC purchased a new position in Kymera Therapeutics in the fourth quarter valued at approximately $2,123,000. T. Rowe Price Investment Management Inc. lifted its position in shares of Kymera Therapeutics by 3.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock valued at $49,001,000 after buying an additional 18,524 shares during the last quarter. Invesco Ltd. lifted its position in shares of Kymera Therapeutics by 46.3% during the 4th quarter. Invesco Ltd. now owns 116,747 shares of the company’s stock valued at $9,084,000 after buying an additional 36,940 shares during the last quarter. Vident Advisory LLC grew its stake in shares of Kymera Therapeutics by 6.5% during the 4th quarter. Vident Advisory LLC now owns 7,581 shares of the company’s stock worth $590,000 after acquiring an additional 465 shares during the period. Finally, Mackenzie Financial Corp purchased a new stake in Kymera Therapeutics in the 4th quarter worth about $270,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.